Provided by Tiger Trade Technology Pte. Ltd.

Amphastar Pharmaceuticals

19.01
-0.5200-2.66%
Post-market: 19.010.00000.00%19:59 EDT
Volume:346.02K
Turnover:6.67M
Market Cap:862.49M
PE:9.36
High:19.64
Open:19.37
Low:18.92
Close:19.53
52wk High:31.26
52wk Low:17.03
Shares:45.37M
Float Shares:34.22M
Volume Ratio:0.67
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.03
EPS(LYR):2.03
ROE:12.90%
ROA:6.37%
PB:1.09
PE(LYR):9.36

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 06, 2025

Amphastar Director Floyd F. Petersen Reports Sale of Common Shares

Reuters
·
Nov 06, 2025

Should Amphastar’s (AMPH) Exclusive 10-Year BAQSIMI Deal in Greater China Prompt Investor Action?

Simply Wall St.
·
Oct 26, 2025

Amphastar Pharmaceuticals Inc - on Oct 21, Co's Unit and Chengong Enter Distribution Agreement - SEC Filing

THOMSON REUTERS
·
Oct 25, 2025

Amphastar Pharmaceuticals Inc - Chengong Appointed Exclusive Distributor for Baqsimi in Greater China - SEC Filing

THOMSON REUTERS
·
Oct 25, 2025

Amphastar Pharmaceuticals Inc - Agreement Term Is 10 Years With Extension Negotiations Possible - SEC Filing

THOMSON REUTERS
·
Oct 25, 2025

Amphastar Pharmaceuticals Appoints Chengong as Exclusive Distributor for BAQSIMI in Greater China

Reuters
·
Oct 25, 2025

Amphastar Pharmaceuticals: Strategic Shift and Growth Catalysts Justify Buy Rating with $36 Target

TIPRANKS
·
Oct 22, 2025

Can Amphastar Pharmaceuticals (AMPH) Navigate Heightened Trade Tensions to Protect Its Supply Chain Advantage?

Simply Wall St.
·
Oct 13, 2025

Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says

MT Newswires Live
·
Oct 09, 2025

BofA Cuts Price Target on Amphastar Pharmaceuticals to $31 From $32

MT Newswires Live
·
Oct 09, 2025

Amphastar price target lowered to $31 from $32 at BofA

TIPRANKS
·
Oct 09, 2025

Amphastar Pharmaceuticals Director Floyd F. Petersen Reports Sale of Common Shares

Reuters
·
Oct 03, 2025

Amphastar Pharmaceuticals Inc - on Sept 15, Enters Contract Research Agreement With Hanxin - SEC Filing

THOMSON REUTERS
·
Sep 19, 2025

Is Weakness In Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Simply Wall St.
·
Sep 19, 2025